Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for COVID-19 Pneumonia
NCT04371601Phase 1Unknown
- Sponsor
- 900th Hospital of Joint Logistics Support Force of PLA
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human umbilical cord mesenchymal stem cells in COVID-19 pneumonia (2 arms), sponsored by 900th Hospital of Joint Logistics Support Force of PLA. Primary endpoint: Oxygenation Index at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04371601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371601.